163 related articles for article (PubMed ID: 20832548)
1. Sirolimus in liver transplant recipients: a large single-center experience.
Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
[TBL] [Abstract][Full Text] [Related]
4. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
7. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
8. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
9. Indications and management of everolimus after liver transplantation.
Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
Shenoy S; Hardinger KL; Crippin J; Desai N; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Transplantation; 2007 May; 83(10):1389-92. PubMed ID: 17519792
[TBL] [Abstract][Full Text] [Related]
11. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
12. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
14. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
[TBL] [Abstract][Full Text] [Related]
15. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
[TBL] [Abstract][Full Text] [Related]
16. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
[TBL] [Abstract][Full Text] [Related]
17. Conversion to sirolimus in renal transplant recipients: a single-center experience.
Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
[TBL] [Abstract][Full Text] [Related]
18. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
[TBL] [Abstract][Full Text] [Related]
19. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
[TBL] [Abstract][Full Text] [Related]
20. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]